CoChat

Telemedicine and Telehepatology During the COVID‐19 Pandemic

Open access
Fix, Oren K., Serper, Marina · 2020 · Clinical Liver Disease
Cited by 38

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

Potential conflict of interest: Nothing to report. Telemedicine has always had the potential to improve access and reduce the costs of health care. Because of the coronavirus disease 2019 (COVID‐19) pandemic, telemedicine has now become a critical way to deliver clinical care.1 Early in the pandemic, the Centers for Disease Control and Prevention (CDC) recommended that ambulatory facilities delay elective visits to mitigate SARS‐CoV‐2 transmission among patients and health care workers.2 Hospitals and health systems across the United States appropriately canceled nonurgent clinic visits and procedures, which led to a sudden and urgent need to shift to alternative health care delivery models for triage, assessment, and patient care.2 Telemedicine, which includes office visits and other medical services provided at a distance using interactive two‐way telecommunications systems (i.e., real‐time audio and video),3 has the potential to limit the exposure of patients and health care workers to the clinic environment, help preserve the limited supply of personal protective equipment (PPE), and reduce the backlog of deferred patient care resulting from the COVID‐19 pandemic response. In turn, this may mitigate the risks for decompensation, morbidity, and loss to follow‐up that could result from delayed care for patients with liver disease.4 A few prescient hospital systems had already implemented telemedicine programs prior to the pandemic, but the vast majority had not, due in large part to federal and state regulatory and reimbursement limitations. There are many reasons why telemedicine had not gained a foothold in the United States prior to the COVID‐19 pandemic. The Centers for Medicare and Medicaid Services (CMS) places substantial barriers to the use of telemedicine by restricting it to patients who reside in rural areas and who must travel to a local medical facility (e.g., doctor’s office, hospital, dialysis facility, or skilled nursing facility) to receive telemedicine services from a doctor in a remote location.3 Most private payers cover some telemedicine services, and many states have enacted parity laws that require private payers to reimburse the same amount for telemedicine services as analogous in‐person services. In many cases, however, reimbursement for telemedicine services is lower than in‐person services. In addition to the regulatory and reimbursement issues, implementation of telemedicine is limited by technology requirements, such as Health Insurance Portability and Accountability Act (HIPAA)‐compliant audiovisual equipment. As a result, telemedicine adoption has been slow. US lawmakers recognized the critical need to remove barriers to telemedicine care during the COVID‐19 crisis. The Coronavirus Preparedness and Response Supplemental Appropriations Act (H.R. 6074) was signed into law on March 6, 2020, and provides a temporary waiver of many of the CMS restrictions and requirements regarding telemedicine services during the COVID‐19 public health emergency.5 Specifically, the bill waives the rural area requirement and the originating site restrictions, allowing the patient to be located anywhere, including their home, and telemedicine services will be paid at the same amount as in‐person services. On March 17, 2020, the Health and Human Services Office of Civil Rights announced that it would not impose penalties for the good faith provision of telemedicine during the COVID‐19 public health emergency, even if the technologies used may not fully comply with HIPAA requirements.6 Recently, on April 30, 2020, the CMS announced it would temporarily increase payments for telephone visits to match in‐person and video visits.7 Barriers to interstate licensure have largely been lifted. Most states have temporarily waived interstate licensure requirements, whereas others have enabled rapid provision of medical licensure during the current public health emergency. When these barriers to telemedicine were removed, providers, hospitals, and health systems rapidly embraced telemedicine or scaled up existing programs to meet the sudden demand for remote, synchronous patient care. As a result, there has been a sudden and substantial increase in telemedicine visits for urgent and nonurgent ambulatory care both related and unrelated to COVID‐19, and patient satisfaction for telemedicine care has been consistently high.8 The CDC identifies patients with liver disease and immunosuppressed patients to be at higher risk for severe COVID‐19.9 It is therefore imperative that we minimize exposure of patients with liver disease and liver transplant recipients to the health care environment. “Telehepatology,” or telemedicine for advanced liver disease, has the potential to facilitate care of this vulnerable population during this critical time.10 Despite its promise, telehepatology is not a panacea. Some patients with new physical symptoms or recent hepatic decompensation are best evaluated in person but may avoid s

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/cld.971

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 38

Metadata

Authors
Fix, O. K., & Serper, M.
Venue
Clinical Liver Disease
Published
2020-05
Volume
15
Issue
5
Pages
187-190
ISSN
2046-2484 (ISSN-L)
OpenAlex
W3028494121
Cited by
38
References
3
FWCI
5.51
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Telemedicine and Telehepatology During the COVID‐19 Pandemic. https://app.cochat.ai/papers/10.1002/cld.971
The paper
Fix, O. K., & Serper, M. (2020). Telemedicine and Telehepatology During the COVID‐19 Pandemic. Clinical Liver Disease. https://doi.org/10.1002/cld.971

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.